Improved long-term survival after intra-operative single high-dose ATG-Fresenius induction in renal transplantation: A single centre experience

Annals of Transplantation

Volumn 14, Issue 3, 2009, Pages 7-17

  Kaden, Jürgen ^a   May, Gottfried ^a   Völp, Andreas ^b   Wesslau, Claus ^c  

^a VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^b Psy Consult Scientific Services   (Germany)

^c Deutsche Stiftung Organtransplantation   (Germany)

Author keywords

Anti T lymphocyte globulin; ATG induction; Graft survival; Kidney transplantation; Patient survival; Rejection

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; THYMOCYTE ANTIBODY FRESENIUS; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; BODY WEIGHT; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; DEATH; DRUG DOSE REDUCTION; ERROR; EXPERIENCE; FEMALE; GERMANY; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTRAOPERATIVE PERIOD; KAPLAN MEIER METHOD; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MEDICAL DOCUMENTATION; MEDICAL RECORD; METHODOLOGY; MIDDLE AGED; MORTALITY; PHYSIOLOGY; POSTOPERATIVE INFECTION; RETROSPECTIVE STUDY; RISK REDUCTION; SALIVA; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; ANTILYMPHOCYTE SERUM; CHILD; FEMALE; GERMANY; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRAOPERATIVE PERIOD; KAPLAN-MEIERS ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; T-LYMPHOCYTES; YOUNG ADULT;

EID: 70349115533     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Barth RF, Southworth J, Burger GM: Studies on heterologous antilymphocyte and antithymocyte sera. J Immunol, 1968; 101: 282-91
2. James K, Milne J: The effect of antilymphocytic antibody on the primary immune response of mice to sheep erythrocytes, bovine serum albumin, and type III pneumococcus polysaccharide. Transplantation, 1971; 12:109-13
3. Biesecker H, Fitch FW, Rowley DA, Stuart FP: Cellular and humoral immunity after allogeneic transplantation in the rat. Transplantation, 1973; 16: 441-50
4. Okumura K, Tada T, Ochiai T: Effect of antithymocyte serum on reaginic antibody formation in the rat. J Immunol, 1974; 26: 257-68
5. Ghaffar A, James K: The effect of individual ALG preparationson on the immune response to type III polysaccharide antigens. J Immunol, 1974; 26: 1974-22
6. Reuben C, Sundaram K, Phondke GP: Suppression of primary immune response by heterologous anti-lymphocyte sera. J Immunol, 1978; 34: 223-30
7. Kaden J, Groth J, Oesterwitz H, Schröder K: Passives Enhancement allogener Rattennierentransplantate durch Antikörper gegen nylonädharente Milzlymphozyten. Z UrolNephrol, 1983; 76:413-19
8. Kaden J, May G, Schönemann C et al: Effect of ATG prophylaxis in sensitized and non-sensitized kidney graft recipients. Transplant Int, 1992; 5: S75-78
9. th Conference Japan Transplant Soc, Osaka, 1992; Abstr, p 92
10. Kaden J, May G, Müller P et al: Intraoperative high-dose anti-T-Lymphocyte globulin bolus in addition to triple-drug therapy improves kidney graft survival. Transplant Proc, 1995; 27: 1060-61
11. Abudher MN, Moorhead JF, Fernando ON, Varghese Z: Preoperative ATG bolus treatment increase CsA sensitivity of peripheral blood lymphocytes (PBLS) in renal transplant patients. Transplant Proc, 1999; 31: 3361-64
12. Kaden J: Eleven years intraoperative ATG bolus. A list of successes. Ann Transplant, 2002; 7: 4-10
13. th World Congr Transplant Soc, Montreal, 1998; Abstr 1648, p 319
14. Naujokat C, Berges C, Fuchs D et al: Antithymocyte globulins suppress dendritic cell function by multiple mechanisms. Transplantation, 2007; 83:485-97
15. + regulatory T cells. J Am Soc Nephrol, 2006; 17: 2844-53
16. th Int Conferece new trends in immunosuppr immunother, Berlin, 2008; Abstr
17. + T cells with normal immuno-regulatory properties in long-term graft outcome. Transplant Int, 2007; 20: 845-55
18. +)? Transplant Int, 2007; 20; 842-4
19. Kaden J, Strobelt V, May G: Short and long-term results after pretransplant high-dose single ATG-Fresenius bolus in cadaveric kidney transplantation. Transplant Proc, 1998; 30: 4011-14
20. Kaden J: Optimal management of induction therapy with ATG in kidney allograft recipients. Int J Immunother, 1999; 15:115-24
21. th Congr Asian Soc Transplant, Poster and Abstr, Singapore 1999
22. Ducloux D, Kazory A, Challier B et al: Long-term toxicity of antithymocyte globulin induction may very with choice of agent: a single-center retrospective study. Transplantation 2004; 7:1029-33
23. Saudek F, Adamec M, Kožnarová et al: Low rejection rate with high-dose ATG bolus therapy in simultaneous pancreas and kidney transplantation. Transplant Proc, 2001; 33; 2304-6
24. Martins L, Fonseca I, Almeida M et al: Immuno-suppression with antithymocyte globulin in renal transplantation: Better long-term graft survival. Transplant Proc, 2005; 37: 2755-58
25. Wang D, Chen JH, Wu WZ et al: One year results of preoperative single bolus ATG-Fresenius induction therapy in sensitized renal transplant recipients. Transplant Proc, 2007; 39: 69-72
26. Kyllönen LE, Eklund BH, Pesonen EJ, Salmela KT: Single bolus antithymocyte globulin versus basil-iximab induction in kidney transplantation with cyclosporin triple immunosuppression: Efficacy and safety. Transplantation, 2007; 84: 75-82
27. Samsel R, Pliszczynski J, Chmura A et al: Safety and efficacy of high dose ATG bolus administra tion on revascularization in kidney graft patients -long term results. Ann Transplant, 2008; 13: 32-39
28. Bock HA, Gallati H, Zürcher RM et al: A randomized prospective trial of prophylactic immunosuppression with ATG-Fresenius versus OKT3 after renal transplantation. Transplantation, 1995; 59: 830-40
29. Yussim A, Shapira Z: Single-bolus high-dose ATG for prophylaxis of rejection in renal transplantation - a prospective, randomize study. Transplant Int, 2000; 13: S293-94
30. Tullius SG, Pratschke J, Strobelt V et al: ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results. Transplant Proc, 2003; 35: 2100-1
31. Kaden J, Strobelt V, Oesterwitz H etal: Monitoring of renal allograft rejection with fine needle aspiration biopsy and serum C-reactive protein. Transplant Proc, 1987; 19: 1657
32. Groth J, Schonemann C, Kaden J, May G: Dynamics of donor-reactive IgG, IgA and IgM antibodies against T and B lymphocytes early after clinical kidney transplantation using flow cytometry. Transplant Immunol, 1996; 4: 215-19
33. Wesslau C, Scholz D, May G, Mebel M: Erfassung von Organspendern - Ergebnisse und Erfahrungen mit dem Organspendemodell Berlin-Potsdam-Frankfurt (Oder). Z Klin Med, 1990; 45: 197-200
34. Hammer C, Thein E: Visualization of the effect of polyclonal antithymocyte globulins on adhesion of leukocytes. Transplant Proc, 2002; 34: 2486-87
35. Chappell D, Beiras-Fernandez A, Hammer C, Thein E: In vivo visualization of the effect of polyclonal antithymocyte globulins on the microcirculation after ischemia/reperfusion in a primate model. Transplantation, 2006; 81: 552-58